Xcout Intel
Myricx Bio
Myricx Bio is a UK biotech company headquartered in London. It specializes in the discovery and development of a novel class of selective cytotoxic payloads for Antibody-Drug Conjugates (ADCs).
Subscribe to see Myricx Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Myricx Bio at a glance
Myricx Bio is a biotechnology company headquartered in United Kingdom. It has raised at least $115M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $114M in July 2024. Xcout tracks 6 named people at Myricx Bio, including Mohit Rawat (Chief Executive Officer).
Myricx Bio leadership
- Mohit RawatChief Executive Officer
- Chris MartinChairman and Non Executive Director
- Jayson PunwaniNon Executive Director
- Jonathan TobinNon Executive Director
- Maina BhamanNon Executive Director
- Michael BauerNon Executive Director
Myricx Bio funding rounds
At least $115M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $114M | 1 named | |
| — | $5.8M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Myricx Bio news
Investors
Myricx Bio competitors
A few of Myricx Bio's closest competitors — see the full list of competitors and alternatives →
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Mythic Therapeutics, Inc. is a biotechnology research company headquartered in Waltham, Massachusetts. The company is dedicated to developing a proprietary platform to enhance the effectiveness of antibody-drug conjugates and other antibody-based therapeutics.
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
CrossBridge Bio, Inc. is a medical technology and biopharmaceutical company pioneering an approach to deliver the next generation of stable antibody-drug conjugates (ADCs).
Get Myricx Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Myricx Bio in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access